Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Fundamental Analysis

NASDAQ:MNPR - Nasdaq - US61023L2079 - Common Stock

31.68  +3.14 (+11%)

Fundamental Rating

3

Taking everything into account, MNPR scores 3 out of 10 in our fundamental rating. MNPR was compared to 572 industry peers in the Biotechnology industry. While MNPR has a great health rating, there are worries on its profitability. MNPR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MNPR has reported negative net income.
In the past year MNPR has reported a negative cash flow from operations.
In the past 5 years MNPR always reported negative net income.
In the past 5 years MNPR always reported negative operating cash flow.
MNPR Yearly Net Income VS EBIT VS OCF VS FCFMNPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

The Return On Assets of MNPR (-106.67%) is worse than 77.52% of its industry peers.
MNPR has a Return On Equity of -130.89%. This is in the lower half of the industry: MNPR underperforms 61.24% of its industry peers.
Industry RankSector Rank
ROA -106.67%
ROE -130.89%
ROIC N/A
ROA(3y)-79.42%
ROA(5y)-61.44%
ROE(3y)-100.89%
ROE(5y)-75.25%
ROIC(3y)N/A
ROIC(5y)N/A
MNPR Yearly ROA, ROE, ROICMNPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

MNPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNPR Yearly Profit, Operating, Gross MarginsMNPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

MNPR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MNPR has less shares outstanding
There is no outstanding debt for MNPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MNPR Yearly Shares OutstandingMNPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
MNPR Yearly Total Debt VS Total AssetsMNPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 85.47 indicates that MNPR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 85.47, MNPR belongs to the best of the industry, outperforming 98.94% of the companies in the same industry.
There is no outstanding debt for MNPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 85.47
ROIC/WACCN/A
WACCN/A
MNPR Yearly LT Debt VS Equity VS FCFMNPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

MNPR has a Current Ratio of 5.41. This indicates that MNPR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.41, MNPR is in line with its industry, outperforming 57.70% of the companies in the same industry.
A Quick Ratio of 5.41 indicates that MNPR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.41, MNPR is in line with its industry, outperforming 58.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.41
Quick Ratio 5.41
MNPR Yearly Current Assets VS Current LiabilitesMNPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.28% over the past year.
EPS 1Y (TTM)45.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MNPR will show a very strong growth in Earnings Per Share. The EPS will grow by 25.38% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.7%
EPS Next 2Y5.01%
EPS Next 3Y22.15%
EPS Next 5Y25.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNPR Yearly Revenue VS EstimatesMNPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
MNPR Yearly EPS VS EstimatesMNPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNPR. In the last year negative earnings were reported.
Also next year MNPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNPR Price Earnings VS Forward Price EarningsMNPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNPR Per share dataMNPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as MNPR's earnings are expected to grow with 22.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.01%
EPS Next 3Y22.15%

More info and screens

0

5. Dividend

5.1 Amount

MNPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONOPAR THERAPEUTICS INC

NASDAQ:MNPR (1/21/2025, 8:14:59 PM)

31.68

+3.14 (+11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)N/A N/A
Inst Owners2.32%
Inst Owner Change0%
Ins Owners11.75%
Ins Owner Change1.43%
Market Cap193.25M
Analysts82.22
Price Target27.88 (-11.99%)
Short Float %0.95%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.43%
Min EPS beat(2)-5.05%
Max EPS beat(2)23.9%
EPS beat(4)3
Avg EPS beat(4)15.31%
Min EPS beat(4)-5.05%
Max EPS beat(4)24.1%
EPS beat(8)6
Avg EPS beat(8)12.67%
EPS beat(12)8
Avg EPS beat(12)9.94%
EPS beat(16)11
Avg EPS beat(16)9.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)51.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-215%
EPS NY rev (1m)0%
EPS NY rev (3m)7.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 39.07
P/tB 39.07
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-2.74
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.67%
ROE -130.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.42%
ROA(5y)-61.44%
ROE(3y)-100.89%
ROE(5y)-75.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.41
Quick Ratio 5.41
Altman-Z 85.47
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.14%
EPS Next Y40.7%
EPS Next 2Y5.01%
EPS Next 3Y22.15%
EPS Next 5Y25.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.2%
OCF growth 3YN/A
OCF growth 5YN/A